☆ 4.5 Article

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study

MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

添加到收藏夹

Article Oncology

Current status and future perspective of immune checkpoint inhibitors in colorectal cancer

Cong Zhou et al.

Summary: ICIs are revolutionizing cancer immunotherapy, with significant effects on melanoma and NSCLC. In the case of CRC, patients with high immunogenicity benefit from ICIs, while those with low immunogenicity do not. Ongoing clinical trials aim to improve response to ICIs in CRC patients through better selection and combination strategies.

CANCER LETTERS (2021)

添加到收藏夹

Review Engineering, Biomedical

Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy

Mengying He et al.

Summary: Immune checkpoint blockade therapy has shown potential efficacy in various cancers, but its effectiveness is limited when used alone. Studies have demonstrated that combining ICBT with other treatment modalities such as chemotherapy, radiotherapy, and phototherapy can enhance therapeutic outcomes. However, there are still challenges and potential issues that need to be addressed in the research on ICBT-based synergistic therapies.

ADVANCED HEALTHCARE MATERIALS (2021)

添加到收藏夹

Review Oncology

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review

Josefien W. Hommes et al.

Summary: ICIs have improved cancer patient prognosis by blocking negative feedback mechanisms of the immune system, but can also lead to auto-immune toxicities. Despite numerous studies, no single biomarker has yet been proven to sufficiently predict the development of irAEs.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors

David J. Lee et al.

Summary: In the past decade, immune checkpoint inhibitors (ICIs) have significantly changed the field of cancer treatment. The development of immune-related adverse events (irAEs) is driven by ICI-induced activation of the immune system, with possible mechanisms including activation of cytotoxic T cells, B cells, direct molecular mimicry, intracellular signaling, and gut microbiome composition. More research is needed to understand irAEs and develop effective monitoring and management strategies.

CURRENT CARDIOLOGY REPORTS (2021)

添加到收藏夹

Review Anesthesiology

Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist

Alexandra L. Lewis et al.

BRITISH JOURNAL OF ANAESTHESIA (2020)

添加到收藏夹

Review Oncology

Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)

Wanhai Ke et al.

THORACIC CANCER (2020)

添加到收藏夹

Review Oncology

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors

Xiao-Hui Jia et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

Tomonori Hirashima et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Khan et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Correction Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)

J. B. A. G. Haanen et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

Feifei Teng et al.

CANCER LETTERS (2018)

添加到收藏夹

Review Oncology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis

Daniel Y. Wang et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Medicine, General & Internal

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

Cheng Xu et al.

BMJ-BRITISH MEDICAL JOURNAL (2018)

添加到收藏夹

Article Oncology

Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice

Efimia Boutsikou et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)

添加到收藏夹

Letter Dermatology

Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity

Ryota Tanaka et al.

JOURNAL OF DERMATOLOGICAL SCIENCE (2017)

添加到收藏夹

Review Oncology

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

J. M. Michot et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

Xin Yao et al.

PHARMACOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Article Immunology

Deficiencies of GM-CSF and interferon γ link inflammation and cancer

T Enzler et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.